Selected-GenAtlas references SOURCE GeneCards NCBI Gene Swiss-Prot Ensembl
HGNC UniGene Nucleotide OMIM UCSC
Home Page
FLASH GENE
Symbol AURKA contributors: shn /mct - updated : 24-09-2021
HGNC name aurora kinase A
HGNC id 11393
ASSOCIATED DISORDERS
corresponding disease(s)
Other morbid association(s)
TypeGene ModificationChromosome rearrangementProtein expressionProtein Function
tumoral   amplification    
in breast, ovarian, colon, prostate, neuroblastoma and cervical cancer cell lines
tumoral     --over  
in breast, ovarian with poor prognosis, colon, prostate, neuroblastoma and cervical cancer cell lines
tumoral       loss of function
causes an increased tumor incidence
constitutional       gain of function
abnormally expressed and activated in cells lining PKD-associated renal cysts
constitutional   deletion    
  • in the developing epidermis alters centrosome function of basal keratinocytes and markedly impairs their ability to divide and stratify
    • tumoral     --over  
    simultaneous overexpression of AURKA and CFL1 correlated with lymph node metastasis in thyroid cancer tissue
    Susceptibility to lung cancer
    Variant & Polymorphism other associations between polymorphisms and lung cancer risk
    Candidate gene
  • skin tumor susceptibility gene
    • Marker
    Therapy target
    SystemTypeDisorderPubmed
    cancer  
    Aurora kinase inhibitors are currently in clinical trials for cancer treatment
    cancer  
    E2F3-Aurora-A axis could be an important target for cancer intervention
    cancermuscle 
    targeting expression or activity of this gene is a novel therapeutic strategy for rhabdoid tumors
    tumorkidneypolycystic kidney
    may be a relevant new biomarker or target in the therapy of PKD
    cancerskin 
    therapeutic elimination of Aurora-A prevents the progression of skin and mammary gland tumors
    cancerendocrinethyroid
    possibility of targeting AURKA and CFL1 for more effective treatment of thyroid cancer
    cancerdigestivepancreas
    AURKA and TPX2 may serve as promising targets to be explored for KRAS-mutant PDAC therapy
    ANIMAL & CELL MODELS